TRAIL-PEG Conjugates for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TRAIL-based treatments for autoimmune diseases like rheumatoid arthritis face challenges due to rapid inactivation, low stability, and systemic side effects, including hepatotoxicity, which limit their clinical application, and require frequent injections, making them clinically undesirable.
Innovation Solution
Development of TRAIL-conjugates, specifically linking a TRAIL polypeptide to polyethylene glycol (PEG) or its derivatives, which extends the biological half-life and allows for less frequent administration, such as once weekly, without the need for local injection or delivery vehicles, and can be combined with other active agents like TNF-α inhibitors for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRAIL is used to treat autoimmune diseases, then therapeutic efficacy is improved, but biological half-life is shortened due to rapid inactivation
Solution Approach 1:
The patent modifies the chemical structure of TRAIL by conjugating it with polyethylene glycol (PEG) chains of varying molecular weights. This chemical modification changes the physical and chemical parameters of TRAIL, specifically increasing its molecular size and hydrodynamic radius, which protects it from rapid renal clearance and proteolytic degradation, thereby extending its biological half-life while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates composite structures by conjugating TRAIL with PEG polymers to form TRAIL-PEG conjugates. These composite molecules combine the therapeutic properties of TRAIL with the stabilizing and extending properties of PEG, resulting in a molecule that has both the desired biological activity and an extended circulation half-life suitable for weekly or less frequent dosing
2Reliability
If TRAIL is administered frequently to maintain therapeutic levels, then therapeutic efficacy is improved, but patient compliance deteriorates due to frequent injections
Solution Approach 1:
The patent uses PEG conjugation to create TRAIL molecules with extended half-lives that maintain therapeutic levels for longer periods. This allows the administration frequency to be reduced from daily to weekly or less frequent dosing, achieving the same cumulative therapeutic effect with fewer administrations, thereby improving patient compliance without compromising efficacy
3Adaptability or versatility
If TRAIL is administered systemically to treat autoimmune diseases, then therapeutic coverage is improved, but harmful side effects increase due to hepatotoxicity
Solution Approach 1:
The patent modifies TRAIL's pharmacokinetic parameters through PEG conjugation, specifically changing its distribution profile and clearance rate. The extended half-life and altered distribution kinetics reduce the peak plasma concentrations and cumulative exposure of TRAIL to the liver, thereby reducing hepatotoxicity while maintaining adequate therapeutic coverage through sustained lower-level exposure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TRAIL-conjugates effectively reduce joint swelling, inflammatory cell infiltration, and autoantibody levels, while increasing anti-inflammatory regulatory T cells, providing sustained therapeutic effects for at least seven days with reduced side effects and improved stability, and when combined with TNF-α inhibitors, achieve greater therapeutic benefits than monotherapies.
Implementation Method 1
DR4 and DR5 have a death domain, allowing them to trigger caspase-3 activation and apoptosis via recruitment of adaptor molecules and the formation of a Death Inducing Signaling Complex (DISC) when bound to TRAIL
Implementation Method 2
linking a TRAIL polypeptide to polyethylene glycol (PEG) or its derivatives, which extends the biological half-life
Data Source
AI summary
Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory T cells, and methods of slowing the progression of inflammation in a subject include systemically administering to the subject a pharmaceutical composition including an effective amount of a TRAIL-conjugate. Preferably, the TRAIL-conjugate is effective for at least 3 days, more preferably at least 7 days, without being part of a nanocomplex that modulates the circulation half-life or release kinetics of the TRAIL-conjugate. Combination therapies including administering a second active agent, most preferably a TNF-α inhibitor, as well as pharmaceutical composition dosage units including a TRAIL-conjugate and a TNF-α inhibitor in an effective amount for a single once weekly dose for treatment of rheumatoid arthritis are also provided.